Definium Therapeutics explores pharmaceutical LSD science in mental health treatments

Definium Therapeutics explores pharmaceutical LSD science in mental health treatments
Pharmaceutical LSD studied for mental health

Definium Therapeutics is drawing attention to the scientific basis and potential benefits of pharmaceutical LSD for mental health care. The company features Dr. Rakesh Jain, MD, MPH, who shares insights on the current research landscape during an evening walk.

Dr. Jain discusses how LSD, under controlled pharmaceutical settings, could contribute to new approaches in addressing mental health conditions. Definium Therapeutics' initiative aims to increase awareness and understanding of these emerging therapies within the medical community.

Definium Therapeutics recently held an Investor and Analyst Day in New York City to provide an update on its advances in psychedelic treatment development. The company is also scheduled to release its Q1 2026 financial results via a live webcast on May 7. These activities follow ongoing efforts to raise awareness within the medical and investment communities.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.